Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-07-26 (globenewswire.com)
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating...
Read more
2024-06-06 (fiercepharma.com)
Italy opens antitrust case against Novartis, Roche and others, claiming collusion to delay biosim launch
A new antitrust investigation in Italy has ensnared Novartis, Genentech, Biogen and Samsung Bioepis for allegedly colluding to suppress competition of a Lucentis biosimilar in the country.
Read more
2024-05-25 (globenewswire.com)
Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB)
Robbins LLP is Investigating Allegations that Biogen Inc. (BIIB) Misled Investors Regarding its Financial Prospects ...
Read more
2024-05-20 (concurrences.com)
The Italian Competition Authority launches an investigation into suspected pay-for-delay agreements between eight pharma companies concerning a biosimilar drug (Biogen / Samsung / Genentech...)
On May 21, 2024, the Italian Competition Authority (the AGCM or ICA) opened new proceedings against eight pharmaceutical companies to investigate suspected pay-for-delay practices in breach of the…
Read more
2023-03-16 (finanznachrichten.de)
Biogen Inc.: Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
CAMBRIDGE, Mass., March 16, 2023(Nasdaq: BIIB) today announced that the Court of Justice of the European Union decided in favor of Biogen, the European Medicines Agency (EMA), and the European Commission
Read more
2023-02-15 (appliedclinicaltrialsonline.com)
FDA Interactions With Industry Under the Microscope
Probe targets agency’s role in advising on drug testing and submissions.
Read more
2022-12-29 (businessinsider.com)
We read through the 45-page congressional investigation into Biogen's Alzheimer's drug. Here are the 3 most shocking takeaways.
The investigation found that Biogen knew the drug's hefty price tag would make the medication inaccessible to many patients.
Read more
2022-12-29 (washingtonpost.com)
House investigation faults FDA, Biogen for Alzheimer’s drug approval
A scathing report reveals that a working group between the agency and Biogen led to sped-up approval for a costly drug that had already been deemed unlikely to work
Read more
2022-09-28 (krem.com)
Alzheimer's drug shows promise in early results of study
The cause of the crash is under investigation by the Idaho State Police.
Read more
2018-07-13 (fiercepharma.com)
FiercePharmaAsia—Biogen-Eisai Alzheimer’s win, Otsuka deals, Samsung BioLogics criminal probe
Biogen and Eisai's Alzheimer's candidate BAN2401 showed new life as 18-month data showed improvements in both clinical symptoms and amyloid beta plaque in the brain. | Biogen and Eisai 's anti-amyloid candidate makes landmark progress in Alzheimer 's trial; Otsuka signs two M& A deals in antibody
Read more
(valuespectrum.com)
FLUENCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Fluence Energy, Inc. on Behalf of Fluence Stockholders and Encourages Investors to Contact the Firm | Valuespectrum.com
FLUENCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Fluence Energy, Inc. on Behalf of
Read more